Is α-MSH the same as Melanotan?

Melanotan I (afamelanotide) and Melanotan II are synthetic analogues based on α-MSH, modified for improved stability and potency. They share core actions but have different receptor selectivity profiles.

Can α-MSH treat inflammation?

α-MSH has potent anti-inflammatory effects in research, but its short half-life limits direct therapeutic use. Research continues into α-MSH analogues and related approaches for inflammatory conditions.

What is the difference between α-MSH and ACTH?

Both derive from POMC and share some sequence similarity. ACTH primarily stimulates cortisol production (via MC2R), while α-MSH primarily affects pigmentation (MC1R) and has broader melanocortin receptor activity.

Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 1 February 2026

Share:X Post LinkedIn

Immune & Inflammatory•Updated 2026-02-01•5 min read

What Is Alpha-MSH? Benefits, Research & Safety

A melanocortin peptide with pigmentation, anti-inflammatory, and appetite-regulating effects, the natural basis for several therapeutic developments.

Share:X Post LinkedIn

Also known as:

α-MSH

Alpha-Melanocyte Stimulating Hormone

Afamelanotide component

CLimited human evidenceUK: Unlicensed (UK)WADA: Sport status unclear

UK summary: Endogenous melanocortin peptide. Afamelanotide (Scenesse), a stable α-MSH analogue, is licensed in some jurisdictions for erythropoietic protoporphyria; native α-MSH is not a UK medicine for cosmetic or anti-inflammatory use.

Quick Facts

Overview

Alpha-melanocyte stimulating hormone (α-MSH) is a 13-amino acid peptide derived from the proopiomelanocortin (POMC) precursor. It is one of the most evolutionarily conserved peptides, with identical sequences across many species, reflecting its fundamental biological importance. α-MSH was originally identified for its role in stimulating melanin production, leading to skin pigmentation. However, it is now known to have diverse effects including potent anti-inflammatory activity, appetite regulation, and modulation of sexual function. The peptide acts primarily through melanocortin receptors (MCRs), particularly MC1R (pigmentation and anti-inflammatory effects), MC3R and MC4R (energy homeostasis and sexual function), and MC5R (exocrine function). α-MSH is the natural template for synthetic analogues including afamelanotide (Scenesse), which is approved for treating erythropoietic protoporphyria, and bremelanotide (Vyleesi), approved for hypoactive sexual desire disorder. Melanotan I and II are also α-MSH analogues. The potent anti-inflammatory effects of α-MSH have generated research interest in conditions ranging from inflammatory bowel disease to arthritis and acute lung injury. Its ability to counteract inflammation without immunosuppression is particularly attractive.

Evidence standards summary

Alpha-MSH — evidence and risk at a glance

Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.

01Evidence snapshot

CLimited human evidenceOverall grade against our evidence grading methodology.

Endogenous melanocortin peptide. Afamelanotide (Scenesse), a stable α-MSH analogue, is licensed in some jurisdictions for erythropoietic protoporphyria; native α-MSH is not a UK medicine for cosmetic or anti-inflammatory use.

02Human evidence grade

ETheoretical / insufficientStrength of evidence from published human trials.

03Preclinical evidence grade

AStrong human evidenceAnimal-model and in-vitro evidence quality.

04Regulatory status

UK: Native α-MSH not licensed. Afamelanotide (Scenesse) approved for EPP.
EU: Afamelanotide approved for erythropoietic protoporphyria.
Notes: α-MSH itself is not used clinically. Synthetic analogues have various regulatory statuses: afamelanotide is approved for EPP; bremelanotide for HSDD (US only). Melanotan products are not approved.

05Approved medical uses

Erythropoietic protoporphyria (afamelanotide / Scenesse — licensed in EU and US for this rare condition only).

06Unapproved / promotional claims

Cosmetic tanning.
Anti-inflammatory wellness supplement.
Safer than Melanotan II.

07Common internet claims

Marketed by some grey-market vendors as 'native' melanocortin analogue.

08Claim vs evidence

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Safer tanning agent than Melanotan II”	E	No	High	Afamelanotide is licensed only for a rare photodermatosis. Native α-MSH and analogues are not approved for cosmetic tanning.

09Safety uncertainty score

Moderate

Safety profile partly characterised; some signals from observational or preclinical data.

10Known adverse signals

Nausea, fatigue, skin hyperpigmentation, melanocytic nevi changes (need dermatology surveillance with afamelanotide).
MHRA has warned against unlicensed melanotan products.

11Drug-interaction uncertainty

Moderate

Some interaction data published; check with a prescriber for your specific medicines.

12Anti-doping status

WADA: Sport status unclearWADA strict-liability framing applies.

13UK legal position

UK: Unlicensed (UK)

Native α-MSH not licensed. Afamelanotide (Scenesse) approved for EPP.

Read the full UK legal guide → Are peptides legal in the UK?

14EU legal position

Afamelanotide approved for erythropoietic protoporphyria.

15What this page cannot tell you

Whether a grey-market 'alpha-MSH' product contains the labelled peptide.
Long-term safety in healthy adults outside the licensed EPP indication.

16Last reviewed

Last reviewed: 1 February 2026

Next review due: 1 February 2027

Spotted an error or something out of date? Send a correction.

17Citation quality score

BModerate human evidenceQuality of the sources we cite, graded against the evidence grading methodology.

18Research gaps

Outside EPP, therapeutic development is limited.

19Safer alternatives / established care pathways

Dermatology referral for genuine pigmentation concerns.
Sunscreen and self-tanning products for cosmetic concerns.

20Doctor discussion prompts

Questions to ask a qualified clinician

These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

Is this an appropriate dermatology consultation rather than a peptide self-experiment?

Discovery & History

The melanocyte-stimulating hormones were first characterised in the 1950s when Aaron Lerner and colleagues isolated substances from pituitary extracts that darkened frog skin. α-MSH was identified as a key active component. The relationship between α-MSH and ACTH was established when researchers discovered that both derived from the same precursor, proopiomelanocortin (POMC). This explained their overlapping biological activities and established the melanocortin peptide family. Research in the 1980s and 1990s revealed α-MSH's potent anti-inflammatory effects, extending interest beyond pigmentation. Studies showed it could inhibit fever, reduce inflammatory cytokines, and protect tissues from inflammatory damage. The cloning of melanocortin receptors in the 1990s enabled understanding of how α-MSH achieves its diverse effects. This led to structure-activity studies and development of synthetic analogues with specific receptor preferences. Afamelanotide (Melanotan I) was developed as a stable α-MSH analogue and eventually approved (as Scenesse) for erythropoietic protoporphyria, a rare disease causing severe photosensitivity. This represented the first approved therapeutic use of an α-MSH analogue. Research continues into α-MSH-based therapies for inflammatory conditions, though short half-life and broad receptor activity present development challenges.

Mechanism of Action

α-MSH exerts its effects through the melanocortin receptor family: **MC1R Activation (Pigmentation and Anti-Inflammation)** Primary receptor for pigmentation: - Stimulates melanin synthesis in melanocytes - Potent anti-inflammatory effects through NF-κB inhibition - Reduces production of pro-inflammatory cytokines - Expressed on immune cells including macrophages **MC3R and MC4R (Energy and Sexual Function)** Central receptors for appetite and metabolism: - MC4R activation reduces appetite and food intake - MC3R involved in energy homeostasis - Both affect sexual arousal and function - Explains weight and sexual effects of MSH analogues **Anti-Inflammatory Mechanisms** Detailed anti-inflammatory actions: - Inhibition of NF-κB activation - Reduction of TNF-α, IL-1β, IL-6, and other cytokines - Induction of anti-inflammatory IL-10 - Protection of tissues from inflammatory damage - Effects mediated largely through MC1R on immune cells **Antipyretic Effects** α-MSH has potent fever-reducing effects: - Central actions reducing fever - Distinct from anti-inflammatory effects - May involve specific brain circuits **Melanogenesis** The classical effect on pigmentation: - Activation of tyrosinase - Enhanced melanin production - Transfer of melanosomes to keratinocytes - Protective tanning effect

Researched Benefits

Based on preclinical and clinical research findings:

1
Skin pigmentation (therapeutic in certain photosensitivity disorders)
2
Potent anti-inflammatory effects across multiple systems
3
Fever reduction (antipyretic)
4
Appetite regulation
5
Effects on sexual function
6
Potential protection in inflammatory bowel disease, arthritis, and other conditions
7
Basis for approved medications (afamelanotide, bremelanotide)

Claim vs Evidence

How popular claims about Alpha-MSH stack up against the current research, graded using our public evidence grading methodology.

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Safer tanning agent than Melanotan II”	E	No	High	Afamelanotide is licensed only for a rare photodermatosis. Native α-MSH and analogues are not approved for cosmetic tanning.

Theoretical Dosing & Protocols

⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.

Theoretical Dosage	Not administered as native α-MSH; see synthetic analogues
Frequency	N/A for native peptide
Duration	N/A
Notes	Native α-MSH is not used therapeutically due to short half-life. Synthetic analogues (afamelanotide, bremelanotide, melanotan) are used clinically or in research. These have modified structures for improved stability.

Administration Routes

Routes studied in research settings (educational only):

Native α-MSH: Not administered therapeutically
Analogues: Subcutaneous injection, implant (afamelanotide)

Half-Life	Stability
Very short; minutes (native α-MSH)	Rapidly degraded; analogues engineered for stability

Safety Profile & Known Risks

Commonly Reported Side Effects

See synthetic analogues for side effect profiles
Nausea (with some analogues)
Skin darkening
Flushing

Rare Risks & Concerns

Changes to moles (with tanning analogues)
Theoretical melanoma concerns
Unknown long-term effects of chronic melanocortin stimulation

Contraindications

History of melanoma (for tanning analogues)
Multiple atypical moles
Pregnancy
See specific analogue information

UK & EU Regulatory Context

🇬🇧 United Kingdom

Native α-MSH not licensed. Afamelanotide (Scenesse) approved for EPP.

🇪🇺 European Union

Afamelanotide approved for erythropoietic protoporphyria.

α-MSH itself is not used clinically. Synthetic analogues have various regulatory statuses: afamelanotide is approved for EPP; bremelanotide for HSDD (US only). Melanotan products are not approved.

Clinical Studies Summary

Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent.

It also lowers HbA1C and protects cells of the cardiovascular and nervous systems by reducing inflammation and apoptosis. In this review we have explored the link between GLP-1, inflammation, and sepsis.

Front Immunol. 2023View on PubMed

Alpha-melanocyte stimulating hormone (α-MSH): biology, clinical relevance and implication in melanoma.

Collectively, these data suggest that targeting MC1R could serve as an approach in the treatment of metastatic melanoma. In this review, we explore the molecular biology of α-MSH with particular emphasis into its tumor-related properties, whilst elaborating the experimental evidence currently available regarding the interplay between α-MSH/MC1R axis, melanoma and antitumor strategies.

J Transl Med. 2023View on PubMed

Bremelanotide: First Approval.

Bremelanotide is a synthetic peptide analogue of the neuropeptide hormone alpha melanocyte-stimulating hormone (α-MSH) with high affinity for the melanocortin type 4 receptor (thought to be important for sexual function), giving it the potential to modulate brain pathways involved in sexual response. This article summarizes the milestones in the development of bremelanotide leading to this first regulatory approval.

Drugs. 2019View on PubMed

Peptides and aging: Their role in anorexia and memory.

A number of centrally acting neuropeptides have also been shown to modulate cognitive processes. Amyloid-beta peptide in physiological levels is a memory enhancer, while in high (pathological) levels, it plays a key role in the development of Alzheimer's disease.

Peptides. 2015View on PubMed

Alpha-melanocyte stimulating hormone: an emerging anti-inflammatory antimicrobial peptide.

Similar to α-MSH's anti-inflammatory properties, its C-terminal residues also exhibit antimicrobial activity parallel to that of the entire peptide. This review is focused on the current findings regarding the direct antimicrobial potential and immunomodulatory mechanism of α-MSH and its C-terminal fragments, with particular emphasis on the prospects of α-MSH based peptides as a strong anti-infective agent.

Biomed Res Int. 2014View on PubMed

Gene therapy for noninfectious uveitis.

To date, gene therapy approaches using interleukin-10, interleukin-1 receptor antagonist, interferon-alpha, soluble TNF-alpha receptors, and alpha-MSH gene transfer have been used successfully to attenuate experimental animal models of uveitis. This review evaluates these preclinical studies, considers the route to clinical application, and explores future targets and approaches.

Ocul Immunol Inflamm. 2012View on PubMed

Registered Trials & Regulatory Status

Registered trials

Currently recruiting

Furthest phase

none

Approved product

1 of 2 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.

Protocol for Alpha MSH Infusion Study in Patients With Type 2 Diabetes

Status: Unknown · 13 participants · Dasman Diabetes Institute

Conditions: Type 2 Diabetes Mellitus

No results postedNCT06293664

Validation of the Concept of the Autoantibodies Directed Against the Neuropeptides Involved in Food Intake Regulation on the Incidental Cases of Eating Disorders

Status: Completed · 211 participants · University Hospital, Rouen

Conditions: Eating Disorder

No results postedNCT03510533

Alpha MSH in Ocular Disease

Status: Completed · 54 participants · Duke University

Conditions: Advanced Dry Macular Degeneration

Results postedNCT03451578

Adverse event reports (FDA FAERS)

Not applicable: no licensed product contains this peptide, so it is not reported through FAERS. This is an absence of surveillance, not evidence of safety.

Source: ClinicalTrials.gov and openFDA. Updated automatically.

Looking for Alpha-MSH?

Source research-grade Alpha-MSH from a trusted UK supplier — third-party tested with certificate of analysis.

View at Supplier

Frequently Asked Questions

Questions to ask a qualified clinician about Alpha-MSH